OBSOLETE: HIV-related Kaposi sarcoma

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

5 events
Feb 1999

Panretin: FDA approved

Topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.

FDAcompleted
Aug 1997

Taxol: FDA approved

For the second line treatment of AIDS-related Kaposi's sarcoma.

FDAcompleted
Apr 1996

DaunoXome: FDA approved

First line cytotoxic therapy for advanced, HIV related Kaposi's sarcoma.

FDAcompleted
Nov 1988

Intron A: FDA approved

Treatment of selected patients with AIDS-related Kaposi's sarcoma.

FDAcompleted
Nov 1988

Roferon-A: FDA approved

Treatment of AIDS related Kaposi's sarcoma.

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

7 programs

FINANCIAL LANDSCAPE SUMMARY

7

Total programs

7

Open now

4

Copay cards

Copay Assistance4

Roferon-A

Hoffmann-La Roche, Inc.

OpenContact for detailsApply ↗

Taxol

Bristol-Myers Squibb Pharmaceutical Research Institute

OpenContact for detailsApply ↗

DaunoXome

NeXstar Pharmaceuticals, Inc.

OpenContact for details

Intron A

Schering Corporation

OpenContact for details

Patient Assistance Programs3

Panretin

Advanz Pharma (US) Corp.

OpenContact for details

POMALYST�

Celgene Corporation

OpenContact for details

Doxil

Johnson & Johnson Pharmaceutical Research & Dev.

OpenContact for details

View all support programs on disease page →

Approved Treatments

6 FDA-approved

Panretin

(Alitretinoin)Orphan drug

Advanz Pharma (US) Corp.

Retinoid [EPC]

12.1 Mechanism of Action Alitretinoin (9-cis-retinoic acid) is a naturally occurring endogenous retinoid that binds to and activates all known intrace...

Approved Feb 1999FDA label ↗

DaunoXome

(Daunorubicin citrate liposome injection)Orphan drug

NeXstar Pharmaceuticals, Inc.

Approved Apr 1996

Roferon-A

(Interferon alfa-2a (recombinant))Orphan drug

Hoffmann-La Roche, Inc.

Approved Nov 1988

Intron A

(Interferon alfa-2b (recombinant))Orphan drug

Schering Corporation

Approved Nov 1988

Doxil

(doxorubicin HCL liposome injection)Orphan drugstandard

Johnson & Johnson Pharmaceutical Research & Dev.

12.1 Mechanism of Action The active ingredient of DOXIL liposomal infusion is doxorubicin hydrochloride. The mechanism of action of doxorubicin hydroc...

FDA label ↗

POMALYST�

(pomalidomide)Orphan drugaccelerated

Celgene Corporation

Thalidomide Analog [EPC]

12.1 Mechanism of Action Pomalidomide is an analogue of thalidomide with immunomodulatory, antiangiogenic, and antineoplastic properties. Cellular act...

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for OBSOLETE: HIV-related Kaposi sarcoma.
Search all trials →
Search clinical trials for OBSOLETE: HIV-related Kaposi sarcoma

Recent News & Research

No recent news articles indexed yet for OBSOLETE: HIV-related Kaposi sarcoma.
Search PubMed for OBSOLETE: HIV-related Kaposi sarcoma

Browse all OBSOLETE: HIV-related Kaposi sarcoma news →

Specialist Network

No specialists currently listed for OBSOLETE: HIV-related Kaposi sarcoma.

View all OBSOLETE: HIV-related Kaposi sarcoma specialists →

Quick Actions